Ilyang Pharmaceutical Co Ltd (007575) — Capital Reinvestment Ratio
Ilyang Pharmaceutical Co Ltd (007575) has a Capital Reinvestment Ratio of 1.47x as of June 2025, meaning it reinvests 1% of its operating cash flow (₩2.26 Billion) in capital expenditures (₩3.32 Billion). Check Ilyang Pharmaceutical Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Ilyang Pharmaceutical Co Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks Ilyang Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see 007575 cash generation efficiency.
Annual Capital Reinvestment Ratio for Ilyang Pharmaceutical Co Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for Ilyang Pharmaceutical Co Ltd from 2014 to 2024. See Ilyang Pharmaceutical Co Ltd (007575) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 7.23x | ₩5.61 Billion | ₩40.62 Billion | ▲ +1448.0% |
| 2023 | 0.47x | ₩14.62 Billion | ₩6.83 Billion | ▲ +242.8% |
| 2022 | 0.14x | ₩29.94 Billion | ₩4.08 Billion | ▼ -29.2% |
| 2021 | 0.19x | ₩67.02 Billion | ₩12.91 Billion | ▲ +8.8% |
| 2020 | 0.18x | ₩57.48 Billion | ₩10.17 Billion | ▲ +194.7% |
| 2019 | 0.06x | ₩36.19 Billion | ₩2.17 Billion | ▼ -14.1% |
| 2018 | 0.07x | ₩22.12 Billion | ₩1.55 Billion | ▼ -44.5% |
| 2017 | 0.13x | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.0% |
| 2016 | 0.38x | ₩26.98 Billion | ₩10.31 Billion | ▼ -4.3% |
| 2015 | 0.40x | ₩40.27 Billion | ₩16.07 Billion | ▼ -46.5% |
| 2014 | 0.75x | ₩18.63 Billion | ₩13.89 Billion | — |